Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gimsilumab in COVID-19 ARDS (BREATHE)
NCT04351243Phase 2Completed
- Sponsor
- Kinevant Sciences
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gimsilumab in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), not applicable; "lung injury" is not a specific disease, sponsored by Kinevant Sciences. Started Apr 2020; status: completed.
02
Drugs
gimsilumab
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on NCT04351243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351243.